Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Trial Profile

Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Girentuximab I-124 (Primary) ; Pazopanib; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Diagnostic use
  • Most Recent Events

    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
    • 27 Dec 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 27 Dec 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top